EA201490230A1 - Применение меченых ингибиторов hsp90 - Google Patents

Применение меченых ингибиторов hsp90

Info

Publication number
EA201490230A1
EA201490230A1 EA201490230A EA201490230A EA201490230A1 EA 201490230 A1 EA201490230 A1 EA 201490230A1 EA 201490230 A EA201490230 A EA 201490230A EA 201490230 A EA201490230 A EA 201490230A EA 201490230 A1 EA201490230 A1 EA 201490230A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hsp90 inhibitors
swindle
hsp90
vivo
inhibitors
Prior art date
Application number
EA201490230A
Other languages
English (en)
Inventor
Габриела Чиосис
Тони Тэлдон
Мэри Л. Элпо
Эрика М. Гомес-Дагама
Моника Л. Гусман
Хунлян Цзун
Original Assignee
Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч
Корнелл Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч, Корнелл Юниверсити filed Critical Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч
Publication of EA201490230A1 publication Critical patent/EA201490230A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Изобретение относится к различным способам применения меченых ингибиторов HSP90 для улучшения лечения пациентов со злокачественной опухолью с помощью ингибиторов HSP90, включая способы ex vivo и in vivo определения того, вероятен ли ответ опухоли на терапию ингибитором HSP90.
EA201490230A 2011-07-08 2012-07-06 Применение меченых ингибиторов hsp90 EA201490230A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161506010P 2011-07-08 2011-07-08
PCT/US2012/045864 WO2013009657A1 (en) 2011-07-08 2012-07-06 Uses of labeled hsp90 inhibitors

Publications (1)

Publication Number Publication Date
EA201490230A1 true EA201490230A1 (ru) 2014-06-30

Family

ID=47506428

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490230A EA201490230A1 (ru) 2011-07-08 2012-07-06 Применение меченых ингибиторов hsp90

Country Status (14)

Country Link
US (4) US20140294725A1 (ru)
EP (3) EP2729806B1 (ru)
JP (4) JP6054389B2 (ru)
KR (2) KR102025142B1 (ru)
CN (3) CN109374889B (ru)
AU (3) AU2012282905B8 (ru)
BR (1) BR112014000445A2 (ru)
CA (2) CA2841069C (ru)
DK (1) DK2729806T3 (ru)
EA (1) EA201490230A1 (ru)
ES (2) ES2624982T3 (ru)
HK (1) HK1243175A1 (ru)
MX (2) MX347607B (ru)
WO (2) WO2013009655A2 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
EP2729806B1 (en) 2011-07-08 2017-02-22 Sloan-kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
US9604930B2 (en) 2012-12-21 2017-03-28 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
EP2972394A4 (en) * 2013-03-15 2016-11-02 Sloan Kettering Inst Cancer HSP90 TARGETING CARDIAC IMAGING AND TREATMENT THEREOF
CN103279964B (zh) * 2013-04-23 2015-10-28 浙江大学 一种基于prca的pet图像动态重建方法及系统
US10421758B2 (en) * 2013-08-16 2019-09-24 Memorial Sloan-Kettering Cancer Center Selective Grp94 inhibitors and uses thereof
CA2923829A1 (en) 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Targeted therapeutics
JP6497767B2 (ja) * 2013-12-16 2019-04-10 日本化薬株式会社 癌治療におけるｈｓｐ９０阻害剤の抗腫瘍効果を予測する方法
KR102325454B1 (ko) * 2013-12-23 2021-11-16 메모리얼 슬로안 케터링 캔서 센터 방사성표지화를 위한 방법 및 시약
EP2942629A1 (en) * 2014-05-08 2015-11-11 Universität Würzburg Predictive markers for successful cancer immunotherapy
EP3194975A4 (en) * 2014-09-17 2018-05-02 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy
CN108472376A (zh) 2015-10-05 2018-08-31 斯隆－凯特林纪念癌症中心 用于治疗癌症的合理组合疗法
NZ763766A (en) 2017-03-20 2023-07-28 Novo Nordisk Healthcare Ag Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
EP3684949B1 (en) * 2017-09-22 2024-04-17 University of Washington In situ combinatorial labeling of cellular molecules
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
WO2020163795A1 (en) 2019-02-08 2020-08-13 Dewpoint Therapeutics, Inc. Methods of characterizing condensate-associated characteristics of compounds and uses thereof
AU2020274530A1 (en) * 2019-05-15 2021-12-16 Whitehead Institute For Biomedical Research Methods of characterizing and utilizing agent-condensate interactions
CN114729941A (zh) 2019-09-18 2022-07-08 露点治疗公司 筛选凝聚物相关特异性的方法及其用途
US20230357760A1 (en) * 2020-10-02 2023-11-09 The Trustees Of Dartmouth College Method and agent for treating/preventing neurodegenerative disease and associated neuroinflammation and for evaluating putative prophylactics/therapeutics for treating/preventing neurodegenerative disease and neuroinflammation
CN113025715A (zh) * 2021-03-23 2021-06-25 中山大学附属第一医院 Hop在预测胃癌预后中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7156111B2 (en) * 2001-07-16 2007-01-02 Akrion Technologies, Inc Megasonic cleaning using supersaturated cleaning solution
JP2005520795A (ja) * 2001-12-12 2005-07-14 コンフォーマ・セラピューティクス・コーポレイション Ｈｓｐ９０阻害活性を有するプリン類似体
US20040121971A1 (en) * 2002-12-20 2004-06-24 Gang Chen Therapeutic use of tumor necrosis factor-alpha mutein
EP1457499A1 (en) 2003-03-12 2004-09-15 Tufts University School Of Medicine Inhibitors of extracellular Hsp90
US7959915B2 (en) * 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
WO2005012482A2 (en) * 2003-06-30 2005-02-10 Sloan-Kettering Institute For Cancer Research Assay for identification of bioactive compounds that interact with heat shock protein 90
NZ546044A (en) 2003-08-29 2009-09-25 Vernalis Cambridge Ltd Pyrimidothiophene compounds
GB0323810D0 (en) * 2003-10-10 2003-11-12 Cancer Rec Tech Ltd Pyridothiophene compounds
WO2005043121A2 (en) * 2003-10-31 2005-05-12 Vitatex, Inc. Blood test prototypes and methods for the detection of circulating tumor and endothelial cells
US9403828B2 (en) * 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) * 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
JP2009512860A (ja) * 2005-10-21 2009-03-26 バイエル ヘルスケア エルエルシー がんの予測及び予後の検査方法、並びにがん治療のモニタリング
DE102006023336A1 (de) 2006-05-18 2007-11-22 Merck Patent Gmbh 1,5-Diphenyl-pyrazole II
US8318790B2 (en) 2006-05-25 2012-11-27 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US10336757B2 (en) 2006-06-30 2019-07-02 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of HSP90
US8580519B2 (en) * 2006-11-27 2013-11-12 University Of Maryland, Baltimore Use of plasma HSP90 related to malignancy
US20090092974A1 (en) * 2006-12-08 2009-04-09 Asuragen, Inc. Micrornas differentially expressed in leukemia and uses thereof
JP2010526280A (ja) * 2007-04-13 2010-07-29 ファーマサイクリックス，インク． ヒストンデアセチラーゼインヒビターの薬効バイオマーカーとしてのカルシウム流動
JP2011501731A (ja) * 2007-09-10 2011-01-13 ユニバーシティ オブ マサチューセッツ ミトコンドリア標的化抗腫瘍剤
US20100215575A1 (en) * 2007-10-12 2010-08-26 Transmolecular, Inc. Systemic Administration of Chlorotoxin Agents for the Diagnosis and Treatment of Tumors
MX2010006154A (es) * 2007-12-07 2010-09-24 Bipar Sciences Inc Tratamiento del cancer con combinaciones de inhibidores de la topoisomerasa e inhibidores de la poli-adp-ribosa-polimerasa.
EP2274617A4 (en) * 2008-04-10 2011-11-09 Massachusetts Inst Technology METHODS FOR IDENTIFYING AND USING AGENTS TARGETING CANCER STEM CELLS
US20110319415A1 (en) 2008-08-18 2011-12-29 Universit+e,uml a+ee t zu K+e,uml o+ee ln Susceptibility to HSP90-Inhibitors
US9567318B2 (en) * 2009-08-17 2017-02-14 Memorial Sloan-Kettering Cancer Center Substituted pyrimidine compounds and uses thereof
LT2486039T (lt) 2009-10-07 2016-10-10 Sloan Kettering Institute For Cancer Research Purino dariniai, naudingi kaip hsp90 slopikliai
CA2779843A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
EA201391334A1 (ru) 2011-04-05 2014-06-30 Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч Ингибиторы hsp90
WO2012138896A1 (en) 2011-04-05 2012-10-11 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
KR102027448B1 (ko) 2011-04-28 2019-10-01 슬로안-케테링인스티튜트퍼캔서리서치 Hsp90 병용요법
EP2729806B1 (en) 2011-07-08 2017-02-22 Sloan-kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
EP2972394A4 (en) 2013-03-15 2016-11-02 Sloan Kettering Inst Cancer HSP90 TARGETING CARDIAC IMAGING AND TREATMENT THEREOF
WO2015089402A1 (en) 2013-12-12 2015-06-18 The University Of Chicago Methods and compositions related to hsp90 inhibitors and breast cancer
EP3194975A4 (en) 2014-09-17 2018-05-02 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy

Also Published As

Publication number Publication date
US20210138091A1 (en) 2021-05-13
CN104081203B (zh) 2018-07-31
BR112014000445A2 (pt) 2017-06-27
KR102138218B1 (ko) 2020-07-28
US20140294725A1 (en) 2014-10-02
AU2012282905B8 (en) 2017-08-31
AU2012282903A1 (en) 2014-02-13
CN109374889B (zh) 2022-04-19
EP2729806B1 (en) 2017-02-22
CA2841069C (en) 2021-11-23
CN109374889A (zh) 2019-02-22
KR20140075667A (ko) 2014-06-19
MX2014000286A (es) 2015-03-06
NZ620634A (en) 2016-07-29
ES2624982T3 (es) 2017-07-18
EP3208615A2 (en) 2017-08-23
JP6662759B2 (ja) 2020-03-11
WO2013009657A1 (en) 2013-01-17
AU2012282905A8 (en) 2017-08-31
AU2012282905B2 (en) 2017-04-06
WO2013009655A3 (en) 2013-05-10
CN104081206B (zh) 2017-06-09
AU2017204369A1 (en) 2017-07-20
US20140242602A1 (en) 2014-08-28
KR20170042805A (ko) 2017-04-19
HK1243175A1 (zh) 2018-07-06
US20240058482A1 (en) 2024-02-22
CA2841173A1 (en) 2013-06-17
JP6054389B2 (ja) 2016-12-27
KR102025142B1 (ko) 2019-09-26
CA2841173C (en) 2022-06-21
EP3709022A1 (en) 2020-09-16
JP2014525908A (ja) 2014-10-02
US9555137B2 (en) 2017-01-31
JP2014527620A (ja) 2014-10-16
JP6218147B2 (ja) 2017-10-25
EP2729806A1 (en) 2014-05-14
EP3208615B1 (en) 2019-10-09
MX347607B (es) 2017-05-04
CA2841069A1 (en) 2013-01-17
CN104081203A (zh) 2014-10-01
WO2013009655A2 (en) 2013-01-17
EP2729806A4 (en) 2015-04-01
MX2014000292A (es) 2015-03-06
CN104081206A (zh) 2014-10-01
DK2729806T3 (en) 2017-05-15
ES2766623T3 (es) 2020-06-12
US11607465B2 (en) 2023-03-21
JP2017121233A (ja) 2017-07-13
AU2012282905A1 (en) 2014-02-13
JP2019194232A (ja) 2019-11-07
AU2017204369B2 (en) 2019-08-01
EP3208615A3 (en) 2017-11-01

Similar Documents

Publication Publication Date Title
EA201490230A1 (ru) Применение меченых ингибиторов hsp90
EA201391208A1 (ru) КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ С ПРИМЕНЕНИЕМ ИНГИБИТОРОВ mTOR/JAK
EA201890512A1 (ru) Способы лечения пациентов со злокачественными опухолями с использованием ингибиторов фарнезилтрансферазы
EA201100335A8 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
MX358517B (es) Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon.
EA201390465A1 (ru) Двойные ингибиторы мэн и фрэс для лечения кастрационно-резистентного рака простаты и остеобластических метастазов в кости
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
EA201290901A1 (ru) Фитоканнабиноиды для лечения злокачественной опухоли
EA201201186A1 (ru) ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
TR201904980T4 (tr) Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar.
EA201490369A1 (ru) Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
BR112013002012A2 (pt) métodos e composições para terapia de câncer de fígado
MY161237A (en) Combination therapy comprising a cdk4/6 inhibitor and a p13k inhibitor for use in the treatment of cancer
WO2011146568A8 (en) Predicting response to a her inhibitor
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
MX2014011500A (es) Diagnosticos y tratamientos relacionados a inhibidores her3.
MX2015004610A (es) Metodo para diagnostico, pronostico y tratamiento de metastasis de cancer de prostata usando c-maf.
BR112014012495A2 (pt) método in vitro, kit, inibidor de egfr e método de tratamento de pacientes afetados com câncer
MX369028B (es) Anti-progestinas para ser usadas en un metodo para inhibir el crecimiento de un tumor susceptible a inhibición del crecimiento por anti-progestinas.
EA201401353A1 (ru) Биомаркеры для определения эффективной ответной реакции на лечение пациентов с гепатоцеллюлярной карциномой (гцк)
WO2012135714A3 (en) Serine biosynthesis pathway inhibition for treatment of cancer
EA201590700A1 (ru) Новый способ получения соединений для применения при лечении рака
PH12015500867B1 (en) Treatment of prostate cancer with tor kinase inhibitors